Exicure Inc (XCUR) - News Archive

: In the fast-paced world of pharmaceutical innovation, maintaining a robust presence on the financial markets is crucial. Exicure, Inc. a biotechnology company pioneering the development of therapies based on its propr...

Exicure, Inc. Receives Nasdaq Hearing Panel Extension Amidst Financial Challenges and Improved ROA RankingExicure, Inc. recently announced that it has received an extension from the Nasdaq Hearings Panel as the company...

Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing nucleic acid-based therapeutics, has recently received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq...

In a recent development, Exicure, Inc. (Nasdaq: XCUR), a renowned biotechnology company with a focus on developing nucleic acid therapeutics, has received a delisting determination notice from The Nasdaq Stock Market LL...

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisCHICAGO - Exicure, Inc. (NASDAQ:XCUR), a renowned developer of nucleic acid therapi...